ARGOMENTO: BOOKS > MEDICINA E OMEOPATIA > SCIENZE INFERMIERISTICHE > TESTI GENERALI

kröger nicolaus (curatore); gribben john (curatore); chabannon christian (curatore); yakoub-agha ibrahim (curatore); einsele hermann (curatore) - the ebmt/eha car-t cell handbook

The EBMT/EHA CAR-T Cell Handbook

Name: The EBMT/EHA CAR-T Cell Handbook
Price: 41,78 € EUR
Availability: InStock
Author: Kröger Nicolaus (Curatore); Gribben John (Curatore); Chabannon Christian (Curatore); Yakoub-Agha Ibrahim (Curatore); Einsele Hermann (Curatore)
ISBN: 9783030943523

kröger nicolaus (curatore); gribben john (curatore); chabannon christian (curatore); yakoub-agha ibrahim (curatore); einsele hermann (curatore)

Disponibilità: Normalmente disponibile in 15 giorni

PREZZO
43,98 €

NICEPRICE
41,78 €

SCONTO
5%

Acquista

Questo prodotto usufruisce delle SPEDIZIONI GRATIS
selezionando l'opzione Corriere Veloce in fase di ordine.

Pagabile anche con Carta della cultura giovani e del merito, 18App Bonus Cultura e Carta del Docente

Dettagli

Genere:Libro

Lingua: Inglese

Editore:

Springer

Pubblicazione: 02/2022

Edizione: 1st ed. 2022

Trama

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.

Sommario

1. Introduction

N Kröger, J Gribben, C Chabannon, H Einsele, I Yakoub-Agha

2. The science behind CAR-T Cells

J Gribben.

2. Structure of and signaling through the Chimeric Antigen Receptor

3. Genetic engineering of autologous or allogeneic immune effector cells

4. What defines a good tumor antigen? Minimizing or managing on target / off tumor and off target / off tumor effects

5. Mechanisms of resistance to CAR-T

6. The European landscape for preclinical and early clinical research

Chapter 3. Manufacturing CAR-T Cells: the supply chain.

C Chabannon.

7. Providing the starting material to the manufacturer of an approved and commercially available autologous CAR-T Cell treatment

8. Receiving, handling, storage, distribution, thawing and administration of the Gene Therapy Medicinal Product (GTMP) shipped from the manufacturing facility

9. Point-of-Care (POC) manufacturing of autologous CAR-T Cells

10. Off-the shelf allogeneic CAR-T Cells or other Immune Effector Cells (IECs) for the future

4. Clinical indications for CAR-T Cells.

H Einsele.

11. Pediatric Acute Lymphoblastic Leukemia (ALL)

12. Adult Acute Lymphoblastic Leukemia (ALL)

13. Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma

14. Mantle Cell Lymphoma

15. Chronic Lymphocytic Leukemia

16 Indolent lymphomas

17. Multiple Myeloma

18. Developments in other hematological malignancies

i. Other lymphoid malignancies

ii. Myeloid Malignancies

i. Developments in solid tumors

5. Clinical management of patients treated with CAR-T Cells.

I Yakoub-Agha.

19. Bridging chemotherapy/ general chapter

i. Adult ALL

ii. Pediatric and young adult ALL

iii. DLBCL, FL and indolent lymphomas

iv. Multiple myeloma

20. Lymphodepleting Conditioning Regimens

21. Management of Cytokine Release Syndrome (CRS)

22. Management of Immune effector Cells Associated Neurotoxicity Syndrome (ICANS)

23. Management of hypogammaglobulinemia and B-cell aplasia

24. Management of myelotoxicity(aplasia) and infectious complications

25. Management of other toxicities

26. ICU

i. Post CAR-T cell therapy (consolidation and relapse)

i. ALL

ii. Lymphomas

iii. MM

27. Immune monitoring

28. Long-term follow-up and late effects

6. Access to CAR-T cells.

N Kröger

29. The regulatory framework for CAR-T cells in Europe: current status and foreseeable changes

30. Center qualification by competent authorities and manufacturers

31. How can accreditation bodies such as JACIE or FACT support centers in getting qualified?

32 Educational needs for physicians

33. Educational needs for nurses

34 Educational needs for pharmacists

25. Educational needs for Cell Collection and Cell Processing Facility personnel

36. GoCART project

37. Patient referral

38 Treatment coverage and reimbursement

39. Assessing the medical value of CAR-T Cells

40 What do patients want? The importance of patient reported outcome

Autore

Nicolaus Kröger MD, is the current EBMT President, Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center, Hamburg - Eppendorf, Germany

John G. Gribben, MD DSc FRCP FRCPath, FMedSci, is the Past President of EHA, Professor of Medical Oncology and Director of Stem Cell Transplantation at Saint Bartholomew's Hospital, Queen Mary School of Medicine, University of London, UK

Christian Chabannon, MD, PhD, is the current chair of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT, is the Head and Qualified Person of the Cell Collection and Cell Processing Facility at Institut Paoli-Calmettes, the Coordinator of the "Centre d’Investigations Cliniques en Biothérapies de Marseille", and a Professor of Cell Biology at Aix-Marseille University, France

Ibrahim Yakoub-Agha, MD, PhD, is the current chair of the Chronic Malignancies Working Party of the EBMT and holds the position of coordinating professor for the Department of Hematology at Lille Faculty of Medicine, France

Hermann Einsele, MD, FRCP, is Full Professor of Internal Medicine and has been Director of the Department of Internal Medicine II of the University Hospital Würzburg, Germany